VIVES is a multi-sector fund that invests in projects with a positive societal impact
ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapies providing broad protection against viral infections, including coronaviruses. It is...
CISSOID is the leader in high temperature semiconductor solutions, delivering standard products and custom solutions for power management, power conversion and signal conditioning in extreme...
Emolytics is a spin-off company of UCLouvain (Belgium) which is closely supported by the Louvain Technology Transfer Office. The technology originated in the University's research center in 2009 as a...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Gael Rouvroy, CEO intoPIX :
"VIVES fund has been a great partner in early and mature stages of intoPIX. They recognized the potential of the market and the technology with a primary recognition for...
Philippe Mengal, past CEO Greenwatt :
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union
No adverse events
BiocSol succeeds in its ambition to raise a total of €10M since inception to fast-track the development of its sustainable crop protection solutions - testament to the sector’s growing interest in its